Business Description
VectivBio Holding AG
NAICS : 325412
SIC : 2834
ISIN : CH1109007893
Description
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.16 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 14.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -27.5 | |||||
| 3-Year EPS without NRI Growth Rate | 4.7 | |||||
| 3-Year FCF Growth Rate | -25.9 | |||||
| 3-Year Book Growth Rate | 104.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 120.34 | |||||
| 12-1 Month Momentum % | 182.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.14 | |||||
| Quick Ratio | 9.14 | |||||
| Cash Ratio | 8.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39 | |||||
| Shareholder Yield % | -47.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -294.52 | |||||
| Net Margin % | -342.84 | |||||
| FCF Margin % | -206.04 | |||||
| ROE % | -59.68 | |||||
| ROA % | -49.58 | |||||
| ROIC % | -260.28 | |||||
| 3-Year ROIIC % | 329.46 | |||||
| ROC (Joel Greenblatt) % | -36269.44 | |||||
| ROCE % | -55.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.44 | |||||
| PB Ratio | 4.95 | |||||
| Price-to-Tangible-Book | 5.65 | |||||
| EV-to-EBIT | -9.27 | |||||
| EV-to-Forward-EBIT | -6.05 | |||||
| EV-to-EBITDA | -9.29 | |||||
| EV-to-Forward-EBITDA | -6.05 | |||||
| EV-to-Revenue | 30.99 | |||||
| EV-to-Forward-Revenue | 4.59 | |||||
| EV-to-FCF | -15.04 | |||||
| Price-to-Net-Current-Asset-Value | 5.65 | |||||
| Price-to-Net-Cash | 5.81 | |||||
| Earnings Yield (Greenblatt) % | -10.79 | |||||
| FCF Yield % | -5.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VECT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VectivBio Holding AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27.341 | ||
| EPS (TTM) ($) | -2.12 | ||
| Beta | 0 | ||
| Volatility % | 71.07 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.118571 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 182.37 | ||
| 52-Week Range ($) | 4.25 - 16.98 | ||
| Shares Outstanding (Mil) | 62.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VectivBio Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VectivBio Holding AG Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
VectivBio Holding AG Frequently Asked Questions
What is VectivBio Holding AG(VECT)'s stock price today?
The current price of VECT is $16.85. The 52 week high of VECT is $16.98 and 52 week low is $4.25.
When is next earnings date of VectivBio Holding AG(VECT)?
The next earnings date of VectivBio Holding AG(VECT) is 2025-02-15 Est..
Does VectivBio Holding AG(VECT) pay dividends? If so, how much?
VectivBio Holding AG(VECT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers